Our Team
John Honts
John Honts is a senior managing director in the firm’s healthcare group, focusing on the biopharma sector.
Mr. Honts has advised on many industry-defining biopharma transactions, including Bristol-Myers on its acquisition of Celegene, Takeda Pharmaceutical on its acquisition of Shire, AstraZeneca on its defense from Pfizer, Sanofi-Aventis on its acquisition of Genzyme, and Wyeth on its sale to Pfizer.
Other notable deals include advising Alnylam on its collaboration with Blackstone; Eli Lilly on its acquisition of Dermira; Agenus on its partnership with Bristol Myers; ArcherDx on its sale to Invitae; Dova Pharmaceuticals on its sale to Sobi; Before Brands on its partnership with Nestlé Health Science; Nexvet Biopharma on its sale to Zoetis; Aetna on its sale to CVS Health; AstraZeneca on the sale of its anti-infectives business to Pfizer and its sale of Myalept to Aegerion; and CVS Health on its acquisition of Omnicare.
Mr. Honts also worked on financing assignments for Apellis, Biohaven, Insmed, Shattuck, Teva and Xeris.
Previously, Mr. Honts was in investment banking at Merrill Lynch in New York and London.